Maxepa

Maxepa is a specific formulation of fish oil containing a standardized ratio of the omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). In clinical research sponsored by Assistance Publique - Hôpitaux de Paris, it has been evaluated for its potential therapeutic effects in postmenopausal women with type 2 diabetes mellitus, specifically focusing on its ability to improve insulin sensitivity, reduce total fat mass, and modulate inflammatory gene expression in adipose tissue. EPA and DHA act as agonists for peroxisome proliferator-activated receptors (PPAR-alpha and PPAR-gamma) and the G protein-coupled receptor GPR120 (FFAR4). These interactions help regulate lipid metabolism, enhance glucose uptake, and suppress pro-inflammatory signaling pathways, which are often dysregulated in metabolic disorders.

Brand names

Maxepa

Other names

eicosapentaenoic acid + docosahexaenoic acidomega-3 fatty acidsomega3 fatty acidsomega 3 fatty acidsn-3 polyunsaturated fatty acidsn3 polyunsaturated fatty acidsn 3 polyunsaturated fatty acidsfish oil